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ABSTRACT
Background
Glioblastoma multiforme (GBM) is the most lethal form of brain cancer. With the available
treatments, survival does not exceed 12–14 mo from the time of diagnosis. We describe a novel
strategy to selectively induce the death of glioblastoma cells and other cancer cells that over-
express the EGF receptor. Using a non-viral delivery vector that homes to the EGF receptor, we
target synthetic anti-proliferative dsRNA (polyinosine-cytosine [poly IC]), a strong activator of
apoptosis, selectively to cancer cells.
Methods and Findings
Poly IC was delivered by means of a non-viral vector: 25kDa polyethylenimine-
polyethyleneglycol-EGF (PEI25-PEG-EGF). EGFR-targeted poly IC induced rapid apoptosis in
the target cells in vitro and in vivo. Expression of several cytokines and ‘‘bystander killing’’ of
untransfected tumor cells was detected in vitro and in vivo. Intra-tumoral delivery of the EGFR-
targeted poly IC induced the complete regression of pre-established intracranial tumors in
nude mice, with no obvious adverse toxic effects on normal brain tissue. A year after treatment
completion the treated mice remain cancer-free and healthy. Similarly, non-viral delivery of poly
IC completely eliminated pre-established breast cancer and adenocarcinoma xenografts
derived from EGFR over-expressing cancer cell lines, suggesting that the strategy is applicable
to other EGFR-over-expressing tumors.
Conclusion
The strategy described has yielded an effective treatment of EGFR over-expressing GBM in an
animal model. If this strategy is translated successfully to the clinical setting, it may actually
offer help to GBM patients. Moreover the elimination of two additional EGFR over-expressing
cancers in vivo suggests that in principle this strategy can be applied to treat other tumors that
over-express EGFR.
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Glioblastoma multiforme (GBM), a brain cancer, is one of
the deadliest human diseases, and cannot be cured by any
therapy available today. The localization of GBM in the
central nervous system and the very solid structure of this
tumor renders it almost impermeable to large particles, such
as viral vectors [1]. A major challenge in the treatment of
GBM is to kill the accessible cancer cells on the surface of the
tumor more rapidly than the rate of replication of the cells.
Otherwise, the unexposed, internal cells can replicate and
compensate for the cells that have just been eliminated. Thus,
an effective treatment for GBM must incorporate the
following features: (a) high selectivity and safety, to avoid
damage to non-cancerous brain tissue; (b) rapid and efﬁcient
cell killing, preferably by simultaneous activation of multiple
killing mechanisms. The simultaneous activation of multiple
killing pathways will ensure tumor cell death, even if one or
several pathways are inactive; and, (c) inhibition of the growth
or killing of neighboring, unexposed tumor cells. This
‘‘bystander effect’’ should assist in eliminating the tumor
before it can re-grow. It should also inhibit the growth of any
tumor cells that may have a different phenotype from the
targeted cells and are not themselves targeted by the
treatment, including cancer stem cells.
In an attempt to meet all these demands in one treatment,
we have taken advantage of the frequent (50%–70%) over-
expression of epidermal growth factor receptor (EGFR) in
GBM [2]. We have attached synthetic, double-stranded RNA
(dsRNA) to a non-viral vector that can home in on EGFR. The
dsRNA is selectively introduced into the cancer cells via
receptor-mediated endocytosis. Double-stranded RNA, fre-
quently expressed in cells infected with viruses, activates a
number of pro-apoptotic processes simultaneously. These
include the dsRNA dependent protein kinase (PKR) and 2,5-
oligo-A synthetase, both of which turn off protein synthesis
[3]. Double-stranded RNA also activates p38 and JNK, and
stimulates the synthesis of pro-apoptotic proteins, such as
IRF3-DRAF1 and NFjB [3–5]. These dsRNA-induced mech-
anisms efﬁciently kill infected cells and induce expression of
anti-proliferative cytokines from the interferon family, there-
by preventing spread of the virus [4].
In order to speciﬁcally introduce poly IC into EGFR over-
expressing cells, we utilized polyethylenimine (25 kDa)-poly-
ethylene-glycol-mEGF (PEI25-PEG-EGF) complexes [6,7]. We
expected this approach to be highly selective, because the
number of EGFRs on tumor cells is 10–100 times higher than
that on non-tumor cells [2]. PEI25-PEG-EGF conjugates are
signiﬁcantly safer than replication-deﬁcient or replication-
competent viruses, in terms of immunotoxic reactions,
inadvertent recombination and viral replication in healthy
cells. Cell death was expected to be fast, because dsRNA
activates cell killing mechanisms within minutes of entering
the cell. Finally, induction of interferons, clinically used
against GBM, was expected to exert a bystander effect and
inhibit the growth of adjacent, untransfected tumor cells.
Methods
Reagents and Assays
Poly IC was obtained from Sigma (Rehovot, Israel). It was
dissolved in DEPC-treated double-distilled H2O. The poly-
ethylenimine (PEI), PEI25, branched and succinimidyl 3-(2-
pyridyldithio) propionate (SPDP) were purchased from
Sigma-Aldrich (Munich, Germany). NHS-PEG-MAL (MW ¼
3400) was obtained from Nektar Therapeutics (Huntsville,
Alabama, United States) and the recombinant mouse EGF
(mEGF) from Pepro Tech EC Ltd. (London, United Kingdom).
The PEI content of the conjugate was determined spectro-
photometrically by TNBS assay at 405 nm. The amount of
dithiopyridine linkers in PEI was determined after reduction
of an aliquot with dithiothreitol (DTT) followed by absorp-
tion measurement of released pyridine-2-thione at 343 nm.
The molar ratio of mEGF: dithiopyridine was determined
spectrophotometrically at 280 and 340 nm. The amount of
dithiopyridine was determined as described [6,7]. The yield of
mEGF(mg)wascalculatedintwoequations.Equation1:A280 (a)
¼ A340 with DTT 3 5.1/8.1. Equation 2: A280 revised ¼
A280 A280 (a). The result of equation 2 was the amount of
mEGF in mg.
The Ellman assay was used for the determination of the
mercapto groups in mEGF-SH. Liquid chromatography of
conjugates was performed with the A ¨ KTA basic system from
Amersham Biosciences (Little Chalfont, United Kingdom).
Melittin (Mel) (D-Mel-SH; e280 ¼ 5570, MW ¼ 2893.6) was
purchased from IRIS Biotech GmbH (Marktredwitz, Ger-
many).
All other chemicals were purchased from Sigma-Aldrich.
Fluorescence Microscopy
Poly IC was labeled with the Fluorescein ULS labeling kit
(Fermentas, Hanover, Maryland, United States) at 1 unit of
ﬂuorescein per 1 lg of poly IC according to the manufac-
turer’s instructions and then condensed with the appropriate
PEI conjugate. Cells were incubated with the complexes in
DMEM/FCS for 4 h at 37 8C and washed twice with PBS. Cells
were viewed on a Zeiss confocal microscope. Green ﬂuo-
rescence was viewed with ﬁlter sets appropriate for ﬂuo-
rescein.
In Vitro Apoptosis Detection
Cells were seeded into 24-well plates at a density of 10,000
in 1 ml of medium per well and grown overnight. After
appropriate treatment cells were washed, ﬁxed and stained
using the Annexin-V-Biotin kit (Roche, Basel, Switzerland)
according to the manufacturer’s instructions. In addition
apoptotic death was also determined by TUNEL assay using
the In situ Cell Death Detection kit (Roche). The brown
colored apoptotic cells were visualized in a microscope,
counted (6 ﬁelds per sample), and photographed using digital
camera.
In Vitro Bystander Effect
For this assay, 500,000 U87MGwtEGFR cells were seeded
onto 6-cm plates, grown overnight in 2 ml of medium, and
transfected with 1 lg/ml poly IC using PEI-PEG-EGFþPEI-Mel
complexes. Medium was collected at 24 h after transfection.
U87MG and U87MGDEGFR ‘‘indicator’’ cells were seeded in
duplicate in 96-well plates (4,000 cells/well) and grown
overnight in 200 ll of medium. Then, 100 ll of medium was
then replaced by the medium collected from the transfected
(þpoly IC) or untransfected ( poly IC) U87MGwtEGFR cells.
Where indicated the medium was pre-incubated for 1 h at
room temperature, with neutralizing polyclonal anti-IFN-a
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California, United States). In NT samples, medium was not
replaced. Growth inhibition was examined 48 h after medium
exchange.
Effect of Targeted Poly IC on 10-d-Old Intracranial Tumor
Models
For this assay, 10,000 U87MGwtEGFR cells per animal were
stereotactically implanted into the brains of 35 nude mice as
described [8]. Five animals were sacriﬁced 10 d later to
evaluate the sizes of the tumors [8]. Then, 200 ll of Alzet
(Alzet, Cupertino, California, United States) osmotic micro-
pumps with intra-tumoral catheters were installed in 20 mice.
Ten mice received (poly IC)PEI-PEG-EGFþPEI-Mel complex
dissolved in HBG buffer [9] at 0.1 lg poly IC/ll buffer (the
dose of poly IC was 0.8 lg/h or 19.2 lg/d), and ten others
received equivalent doses of PEI-PEG-EGFþPEI-Mel com-
plexes only (no poly IC). Ten remaining control animals did
not receive any treatment. The pumps were replaced twice
every 24 h. At day 20 after cell implantation (10 d after
treatment initiation), ﬁve animals from each group were
sacriﬁced to evaluate tumor size as described [8]. Five other
animals in each group were retained for survival analysis [8].
All animal experiments were conducted in accordance with
the Hebrew University guidelines for the care of laboratory
animals.
In Vivo Bystander Effect
For this assay, 5,000 U87MGwtEGFR cells were mixed with
5,000 U87MGDEGFR cells in 5 ll of PBS per animal. The cells
were stereotactically implanted into the brains of 14 nude
mice as described [8]. 10 d later, 200-ll Alzet osmotic
micropumps with intra-tumoral catheters were installed in
12 mice. Six mice received (poly IC)PEI-PEG-EGFþPEI-Mel
(poly IC/conjugate) complexes dissolved in HBG buffer at the
indicated dose (two animals for each dose), and six others
received an equivalent dose of PEI-PEG-EGFþPEI-Mel com-
plexes without poly IC (Conjugate only). The pumps were
replaced twice every 24 h. Survival of the animals was
analyzed as above.
In Vivo Apoptosis Detection
For this assay, 10,000 U87MGwtEGFR cells per animal were
stereotactically implanted into the brains of 12 mice as above.
14 d later, 200-ll Alzet osmotic micropumps with intra-
tumoral catheters were installed in six U87MGwtEGFR-
bearing mice. Three animals received formulated poly IC
(19.2 lg total per animal for 24 h), and three mice received
complexes without poly IC. Six remaining animals received
no treatment. Immediately after termination of infusion (15 d
after cell implantation), animals were sacriﬁced, the brains
were ﬁxed with 4% formalin, embedded in parafﬁn, and
ultra-thin slices were prepared. Slices were then de-parafﬁ-
nized and analyzed by ﬂuorescent immunohistochemistry to
determine apoptosis with the Cell Death Detection kit-TMR
Red, Roche (red ﬂuorescence) and EGFR expression with
FITC conjugated EGFR (internal domain) antibody (green
ﬂuorescence), Biosource (Camarillo, California, United
States).
Synthesis of Mel-PEI25-PEG-mEGF
The synthesis of mEGF-PEG-PEI25 is described elsewhere
[6,7]. mEGF-PEG-PEI25 (83 nmol PEI) was mixed with SPDP
(664 nmol in 100% ethanol) under argon. After 3 h at room
temperature the mixture of about 2 ml was loaded on a gel
ﬁltration column (Sephadex G25 superﬁne; HR10/30; 20mM
HEPES [pH 7.1], 0.5M NaCl; Amersham Biosciences). The
puriﬁed PDP-functionalized conjugate (5 ml) containing 309
nmol of PDP was concentrated to 1.5 ml by speed vac. For the
reaction with Melittin 464 nmol of Mel was weighed out and
dissolved in 0.5 ml of 0.5 M NaCl, 100mM HEPES [pH 7.4]
degassed with argon. Both components were mixed under
argon. After 20 h at room temperature mEGF-PEG-PEI25-Mel
was puriﬁed by gel ﬁltration. To gel ﬁltrate the conjugate, a
Superdex 75 prep grade column 10/30, conditioned with
PEI25br (10 mg PEI25/60 ml gel material) was used. After
dialysis overnight (MWCO 14000; Visking type 27/32; Roth,
Karlsruhe, Germany) against HBS 6 ml of mEGF-PEG-PEI25-
Mel conjugate were obtained; these contained 66 nmol PEI
(1.64 mg), 350 nmol Mel, and 70 nmol EGF.
A431 Xenograft Treatment
Two million A431 cells were implanted subcutaneously into
the left ﬂanks of 15 nude CD-1 mice. When palpable tumors
(average size 10.1 mm
3) had developed, animals were divided
into three groups of ﬁve animals. The complexes were
delivered by intra-tumoral injection twice per day for 6 d.
Five mice received poly IC-Melittin-PEI25-PEG-EGF (poly IC-
MPPE) complex dissolved in HBG buffer at 0.1 lg poly IC/ll
buffer (the dose of poly IC was 15 lg/injection or 30 lg/d), and
ﬁve others received equivalent doses of MPPE complexes only
(no poly IC). Remaining animals did not receive any treat-
ment. Length (a) and width (b) of the tumors were measured
daily with caliper and the tumor size was calculated as ab
2/2.
Control animals were sacriﬁced at day 33 after treatment
initiation. Poly IC treated animals were left for follow up
study to detect recurrence of the tumors.
MDA-MB-468 Xenograft Treatment
Two million MDA-MB-468 cells were implanted over the
mammary fat pad of 15 SCID/non-obese diabetic (NOD) mice.
When palpable tumors (average size 9.8 mm
3) had developed,
animals were divided into three groups of ﬁve animals each.
The complexes were delivered by intra-tumoral injection
once per day for 6 d. Five mice received (poly IC)MPPE
complex dissolved in HBG buffer at 0.1 lg poly IC/ll buffer
(the dose of poly IC was 20 lg/d), and ﬁve others received an
equivalent doses of MPPE complexes only (no poly IC).
Tumor size was calculated as above. Control animals were
sacriﬁced at day 33 after treatment initiation. Poly IC-treated
animals were left for follow-up study to detect recurrence of
the tumors.
Results
Fast and Selective Killing of EGFR Over-Expressing GBM
Cells In Vitro
The PEI25-PEG-EGF complexes efﬁciently delivered poly
IC, killing up to 85% of U87MGwtEGFR cells, which over-
express EGFR (;1 3 10
6 receptors [10]), within 1 h of
transfection (Figure 1A). At poly IC concentrations of up to
10 lg/ml, no signiﬁcant effect was observed on the parental
U87MG cells, which express 100,000 of EGFR per cell [10], on
cells that over-express the mutated D(2–7)EGFR
(U87MGDEGFR), or on glioma cells lacking the EGFR
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lg/ml poly IC, the survival of U87MG and U87MGDEGFR
cells, was inhibited by 20%. U138MG cells, which completely
lack EGFR, were not inhibited at all. The killing effect on
U87MGwtEGFR cells was enhanced 8- to 10-fold when PEI25-
PEG-EGF was partially replaced with the polyethylenimine (2
kDa)-Melittin conjugate PEI2-Melittin (Figure 1A), and more
than 95% of U87MGwtEGFR died within an hour of trans-
fection, again, with no effect on the other glioma cell lines
(Figure 1A). Melittin is a bee venom peptide that facilitates
the release of nucleic acids from the endosome into the
cytoplasm [9,12], thus enhancing the release of poly IC from
the endocytosed vesicle. No signiﬁcant toxic effect of the
complexes without poly IC on any of the cell lines was
detected (Figure S1). Annexin V and TUNEL staining showed
that the majority (70%–90%) of the U87MGwtEGFR cells
died by apoptosis within 1 h of transfection (Figure 1B and
1C). Although fast apoptotic death is not common, it has
occasionally been detected in other cell lines where, like here,
a number of pro-apoptotic pathways are activated simulta-
neously [13,14].
Distribution of the Formulated Poly IC in the Cells
In order to verify selective entrance of the complexes into
the target U87MGwtEGFR cells and its release from endo-
somes ﬂuorescent labeling of poly IC was performed
(Methods). U87MGwtEGFR and U87MG cells were transfected
with the labeled poly IC/PEI-PEG-EGF complex either in
presence or absence of PEI-Mel (Figure 2). Figure 2A shows
Figure 1. (poly IC)PEI-PEG-EGF(þPEI-Mel) Complexes Selectively Kill U87MGwtEGFR Cells
(A) Cells were seeded in duplicate onto a 96-well plate at a density of 5,000 cells in 0.2 ml of medium per well and grown overnight. Cells were then
transfected as described [6,9] with poly IC at the indicated concentrations using either PEI-PEG-EGF or PEI-PEG-EGFþPEI-Mel (w/w ratio PEI-PEG-EGF:PEI-
Mel ¼ 1:10) complexes. Viability was measured by the CellTiter-Glo Luminescent Cell Viability Assay (Promega) according to the manufacturer’s
instructions, at 1 h after transfection.
(B and C) Fast induction of apoptosis by (poly IC)PEI-PEG-EGFþPEI-Mel complexes. Apoptotic death was detected 1 h after transfection by Annexin (B)
and TUNEL (C) assays as described in Methods.
DOI: 10.1371/journal.pmed.0030006.g001
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virtually no signal in U87MG cells. To examine the intra-
cellular distribution, U87MGwtEGFR cells incubated with
ﬂuorescently labeled poly IC/PEI-PEG25-EGF or poly IC/PEI-
PEG25-EGFþPEI-Mel complexes, were washed, and viewed live
to rule out ﬁxation artifacts, using confocal microscopy
(Figure 2B). After 4 h of incubation, poly IC/PEI-PEG25-EGF
complexes appeared in a punctate intracellular pattern,
suggesting entrapment within vesicles (Figure 2B). In con-
trast, poly IC/PEI-PEG25-EGFþPEI-Mel complexes showed
ﬂuorescence dispersed throughout the cytoplasm (Figure
2B). The cytoplasmic ﬂuorescence of the Melittin-containing
complexes suggests that Melittin indeed facilitated release of
the complex into the cytoplasm, by lysis of intracellular
vesicles.
Involvement of PKR in Cell Death
The fast killing effect of the complexes was signiﬁcantly
inhibited by 2-aminopurine (2-AP), a potent inhibitor of PKR
[15], suggesting that this effect is largely mediated by PKR
(Figure 3A). At later time points, 48 and 72 h after
transfection, the protective effect of 2-AP was signiﬁcantly
less pronounced, suggesting that additional cell killing
mechanisms were activated.
In Vitro Bystander Effect
We next investigated whether the poly IC-transfected cells
exerted a bystander effect on untransfected cells (Methods).
Growth medium from poly IC-transfected U87MGwtEGFR
cells inhibited the growth of U87MG and U87MGDEGFR cells
(Figure 3B), which are themselves insensitive to the (poly
IC)PEI-PEG-EGFþPEI-Mel complex (Figure 1A). The bystand-
er effect was less pronounced when U87MGwtEGFR cells
were transfected with targeted poly IC at higher concen-
trations (Figure S2), probably because the transfected cells
died before they could exert the full effect. The bystander
effect was further conﬁrmed by co-culture of U87MGwtEGFR
and U87MGDEGFR cells in the same wells (Figure 3C). A large
fraction of the U87MGDEGFR cells were killed, although they
are themselves almost insensitive to the poly IC complex.
Double-stranded RNA is known to induce the expression of
interferons and other anti-proliferative cytokines. To inves-
tigate whether the bystander effect was caused by interferon,
we incubated medium from transfected U87MGwtEGFR cells
with neutralizing IFNa antibody. This pre-incubation re-
duced the bystander effect on all cell lines by 20%–30%
(Figure 3B), indicating that IFN-a was indeed responsible for
part of the bystander effect. The partial reduction in the
bystander effect suggests that additional cytokines, other than
IFN-a, were also expressed. Using ELISA (IBL, Hamburg,
Germany), we conﬁrmed the presence of IFNa in growth
medium from poly IC-transfected cells. Up to 4 pg/ml IFNa
were generated in the medium of 500,000 U87MGwtEGFR
cells transfected with 2.5 lg/ml of poly IC, but not in the
medium of U87MG or U87MGDEGFR cells treated with the
same complex. No IFN-a was detected in medium from cells
transfected with poly IC at higher concentrations, suggesting
that these cells were killed before they could secrete the
cytokine. IFN-a was also generated in vivo (. 600 pg/g of
Figure 2. Distribution of the Complexes
Cells were seeded into 6-cm plates at a density of 300,000 cells in 2 ml of medium per plate and grown overnight. Cells were then transfected with the
fluorescently labeled poly IC (5 lg/ml) using the indicated conjugates. After 4 h, cells were analyzed by fluorescent microscopy (Methods) for selectivity
of the transfection (A) and intracellular distribution of the complex in the U87MGwtEGFR cells (B).
DOI: 10.1371/journal.pmed.0030006.g002
PLoS Medicine | www.plosmedicine.org January 2006 | Volume 3 | Issue 1 | e6 0129
Cancer-Specific Transfection of dsRNAtumor tissue), speciﬁcally in U87MGwtEGFR tumor xeno-
grafts (Figure 4). Using a Human Cytokine Microarray
(RayBiotech, Norcross, Georgia, United States), we sought to
identify additional cytokines in the medium of poly IC-
transfected cells. Both GROa [16] and IP-10 [17] were
detected. The production of IP-10 and Gro-alpha at high
concentrations in vitro and selectively in tumors in vivo, was
conﬁrmed by cytokine speciﬁc ELISAs (Figure 4). These
cytokines are chemokines responsible for the recruitment of
T-cells to area of expression [16,17].
Formulated Poly IC Eliminates Intracranial GBM Models in
Mice
These encouraging results led us to test the EGFR-targeted
poly IC strategy in vivo. Ten thousand U87MGwtEGFR cells
were implanted into the brains of nude mice as described
(Methods) and the tumors left to grow for 10 d. During this
period, visible tumors developed (Figure 5A). On day 10 after
cell implantation, (poly IC)PEI-PEG-EGFþPEI-Mel complexes
were delivered directly into the tumors at a constant rate for
3 d, using Alzet osmotic micropumps. On day 20 after cell
implantation (7 d after the end of treatment), the tumors had
disappeared completely from (poly IC)PEI-PEG-EGFþPEI-
Mel-treated animals, while the tumors continued to grow in
untreated animals until reaching 36.44 mm
3 (Figure 5A).
Animals that were treated with PEI-PEG-EGFþPEI-Mel alone
(no poly IC), survived for no longer than 32 d, as did
untreated animals (Figure 5B). In contrast, the (poly IC)PEI-
PEG-EGFþPEI-Mel-treated animals are still alive on the day of
submission of this manuscript (more than a year), and show
no signs of increased intracranial pressure. When Melittin
was omitted, the mice died from GBM 57–59 d after cell
implantation (unpublished data). Histopathologic examina-
tion of the brains of the poly IC-treated mice at day 7 after
the end of treatment did not reveal any residual tumors
(Figures 5A and 6A), whereas the control animals had large
tumors (Figures 5A and 6A). Pathological analysis of the
brains at 24 h after treatment initiation showed increased
gliosis in the brains of the animals of all experimental groups
(Figure 6A). This was probably caused by the growing tumors
in the brains. We also detected low inﬁltration of macro-
phages into the tumors in all groups (Figure 6A). None of the
animals treated with poly IC showed any additional histo-
pathological signs of toxicity or brain tissue damage either at
24 h after treatment initiation or at 7 d after the end of the
treatment (Figures 5A and 6A). Similarly, we did not detect
any signiﬁcant increase in inﬁltration of immune cells into
poly IC treated tumors as compared with the untreated
tumors (Figure 6A).
Bystander Effect In Vivo
In the clinical setting, some GBM cells over-express wt
EGFR, whereas neighboring cells express lower levels of EGFR
or over-express truncated EGFR (DEGFR) [2]. As described
above, in culture the EGFR-targeted poly IC-transfected cells
induced the killing of neighboring, untransfected cells
(Figure 3B and 3C). We therefore examined bystander killing
in vivo (Methods). We implanted a mixture of 5000
U87MGwtEGFR and 5000 U87MGDEGFR cells in mice brains
(Figure 5C). The mixed tumors that developed 10 d later were
treated with the targeted poly IC at various doses (Figure 5C).
Control animals survived for no more than 34 d, while mice
that received the lowest dose of poly IC complex (0.2 lg/h)
survived more than 2 times longer. Animals that received
higher doses of formulated poly IC (0.4 lg/h and 0.8 lg/h) are
alive and well on the day of submission of this paper (day
297þ). This very encouraging result is probably due to the
strong bystander effect induced by the slow delivery of the
formulated poly IC. Elimination of the mixed tumor was not
caused by immune reaction since we did not detect increased
inﬁltration of immune cells into the poly IC treated tumors
(Figure 6A).
Formulated Poly IC Induces Apoptosis in U87MGwtEGFR
Cells In Vivo
We next examined the mode of U87MGwtEGFR cell death
induced by the targeted poly IC in vivo. U87MGwtEGFR cells
Figure 3. Cell Killing Mechanisms
(A) Protection of the cells by 2-AP. Cells were grown as in Figure 1A. Cells
were then transfected with poly IC at the indicated concentrations using
PEI-PEG-EGFþPEI-Mel complexes. Where indicated, 2-AP (5 mM) was
added 18 h before transfection and the medium was replaced every 24 h
with medium containing fresh 2-AP. Viability was measured by the
Methylene Blue assay [8].
(B) In vitro bystander effect. U87MGwtEGFR cells were grown and
transfected as described in Methods. U87MG and U87MGDEGFR
‘‘indicator’’ cells were grown in duplicates in 96-well plates. Medium of
the ‘‘indicator cells’’ was then partially replaced by the medium collected
from the transfected (þpoly IC) or untransfected (-poly IC)
U87MGwtEGFR cells (Methods). Where indicated the medium was
preincubated with neutralizing polyclonal anti IFNa antibody. In NT
samples, medium was not replaced.
(C) A total of 4,000 U87MGwtEGFR and U87MGDEGFR cells were seeded
in duplicate onto a 96-well plate at the indicated ratios and grown
overnight. Cells were then transfected with poly IC at the indicated
concentrations using PEI-PEG-EGFþPEI-Mel conjugates. Cell survival was
measured by the Methylene Blue assay 96 h after transfection.
DOI: 10.1371/journal.pmed.0030006.g003
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treated with formulated poly IC. EGFR expression was
monitored with FITC-conjugated EGFR antibody (green
ﬂuorescence). Apoptosis was monitored with the TMR Red
Cell Death Kit (Roche). Apoptosis occurred exclusively in
cells over-expressing the EGFR (Figure 6B). No signiﬁcant red
signal was observed in the surrounding tissue, demonstrating
the high selectivity and low toxicity of the treatment regimen.
Effect of Formulated Poly IC on 15-d-Old Intracranial
Xenografts
Although 10-d tumors used in the survival experiments are
clinically relevant to newly diagnosed GBM in humans (R.
Catane and R. Pfeffer, Division of Neuro-oncology, Tel
Hashomer/Sheba Hospital, personal communication), we
examined whether formulated poly IC is effective against
much larger tumors (Figure 5A). For this purpose we
synthesized Mel-PEI25-PEG-EGF (MPPE, Methods). Although
not observed, there is a possibility of PEI-Mel dissociation
from (poly IC)PEI-PEG-EGFþPEI-Mel complexes. This may
result in decreased release of poly IC to cytoplasm. When
both Melittin and EGF are covalently bound to the same PEI
molecule, the vector should be more efﬁcient and even less
toxic, because Melittin is now covalently linked to the
complex, and therefore there is no possibility of PEI-Mel
leakage. It was also observed that PEI25 conjugates are
signiﬁcantly smaller in size than PEI2 or PEI2þPEI25 con-
jugates (M.O., unpublished data), leading to higher in vivo
transfection efﬁciency.
In order to obtain larger tumors, the intracranially
implanted 10,000 U87MGwtEGFR cells were left to grow for
15 d. The resulted tumors were 13–15 times bigger than the
10-d-old tumors (Figures 5A and 7A). (poly IC)Mel-PEI-PEG-
EGF and (poly IC)MPPE complexes were delivered directly
into the tumors at a constant rate for 3, 4, and 5 d, using Alzet
osmotic micropumps. Animals that were treated with MPPE
alone (no poly IC), survived for no longer than 33 d, as did
untreated animals (Figure 7A). In contrast, the (poly
IC)MPPE-treated animals in all groups are still alive on the
day of submission of this manuscript (day 244þ), and show no
symptoms of GBM.
Formulated Poly IC Destroys Other EGFR Over-Expressing
Cancers In Vitro and In Vivo
We next examined whether our strategy could be imple-
mented for the treatment of other EGFR over-expressing
cancers. We used the A431 (vulval carcinoma, expressing ;2
3 10
6 EGF receptors per cell [18]) and MDA-MB-468 (breast
cancer, similar EGFR expression and EGFR responsiveness to
A-431 cells [19]), both non-engineered cell lines. Figure 7B
shows targeted poly IC induced killing of A431 and MDA-MB-
468 cells, whereas the control U87MG cells remain unharmed.
Figure 7B also demonstrates the enhanced efﬁcacy of the all-
in-one vector MPPE as compared to PEI-PEG-EGFþPEI-Mel
combination formula.
Encouraged by these results, we examined the efﬁciency of
our strategy on models of these cancers in vivo. A431 cells
were implanted subcutaneously into nude mice as described
(Methods) and the tumors left to grow for 10 d. During this
period, tumors of average size 10.1 mm
3 were developed
(Figure 7C). After tumor establishment, (poly IC)MPPE
complexes were injected directly into the tumors twice per
Figure 4. Targeted Poly IC Induces Expression of Cytokines
For this assay, 10,000 U87MGwtEGFR cells were implanted into the brain of nude mice. After 15 d, poly IC was injected with Alzet micropumps for 24 h
at 0.8 lg/hr. After 48 h, animals were sacrificed and the brains were extracted. Tumors (average weight 17.6 mg) and surrounding brain tissue (average
weight 253 mg) were resuspended in Tris-HCl buffer (100 mM Tris, [pH 8.1] with 1% Triton X-100) at 1:10 w/v. Samples were homogenized on ice by
sonication, triturated through 19 gauge needles and spun at 20,0003g. Protease inhibitors were added to supernatant, which was then subjected to
cytokine-specific ELISA.
DOI: 10.1371/journal.pmed.0030006.g004
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(Methods). On day 10 after treatment initiation, the tumors
had disappeared completely from (poly IC)MPPE treated
animals, while the tumors continued to grow in untreated
animals, reaching up to139 mm
3 (Figure 7C).
MDA-MB-468 cells were implanted over mammary fat pads
of female SCID mice and the tumors left to grow for 14 d.
During this period, tumors of average size 9.7 mm
3 developed
(Figure 7C). (poly IC)MPPE complexes were injected directly
into the tumors for 6 d. On day 8 after treatment initiation,
the tumors had disappeared completely from (poly IC)MPPE
animals, while the tumors continued to grow in untreated
animals, reaching 63 mm
3 (Figure 7C).
We did not detect recurrence of any of the tumors in the
follow up study (day 42þ after treatment initiation).
Discussion
Our results suggest that the EGFR-targeted delivery of poly
IC can be implemented in the clinical treatment of GBM, for
which current therapies are essentially ineffective. The
therapeutic approach described here incorporates rapid
and efﬁcient killing of tumor cells by multiple mechanisms,
a strong bystander effect, along with high selectivity. The
localization of GBM in the central nervous system makes it an
attractive candidate for local therapy by slow, constant, intra-
tumoral delivery of the complexes described here (Figure 5).
EGFR-targeted delivery of poly IC should be especially
Figure 5. Targeted Poly IC Eliminates Intracranial GBM Models
(A and B) (poly IC)PEI-PEG-EGFþPEI-Mel complexes eliminate U87MGwtEGFR xenografts. Intracranial U87MGwtEGFR tumors were established and
treated with formulated poly IC as described in Methods. (A) Sizes of the tumors before and after the treatment. (B) Survival of the animals (Methods).
(C) In vivo bystander effect. A mixture of 5,000 U87MGwtEGFR and 5,000 U87MGDEGFR cells was implanted into the brain of nude mice as described in
Methods. The mixed tumors were treated with formulated poly IC (poly IC-/conjugate) at the indicated doses, and control animals received equivalent
doses of PEI-PEG-EGFþPEI-Mel complexes without poly IC (Conjugate only). Survival of the animals was analyzed as above. Mice receiving 0.2lg/h of
poly IC die up to day 75, whereas those receiving 0.4 lg poly IC/h and 0.8 lg poly IC/h are still alive.
DOI: 10.1371/journal.pmed.0030006.g005
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could in principle be the ﬁrst line of treatment, considering
the results reported here. We have previously described an
approach for GBM treatment using viral vectors to induce the
in situ production of cancer-speciﬁc dsRNA within the cancer
cell [8]. The EGFR-targeted synthetic dsRNA approach we
describe now seems to be far superior, probably because we
have achieved rapid delivery of a large dose of longer dsRNA
into the cancer cell. This leads to a very fast response and
induction of a bystander effect so that the tumor is
demolished more rapidly than it can re-grow. Although many
of the immune cells are still present in the nude mice we used,
no signiﬁcant immune reaction against the poly IC treated
tumor was observed (Figure 6A). Most likely absence of the
immune response is due to the fast elimination of the tumor.
An immune reaction might be induced in patients following
treatment that will take signiﬁcantly longer periods of time.
Nevertheless, expression of immunoactive IFN-a and T-cell
chemokines, IP-10 and Gro-a selectively in the tumor (Figure
4) should drive the immune response speciﬁcally against GBM,
reducing potential toxic effects on surrounding brain tissue.
To the best of our knowledge, the strategy described in this
study has yielded the most effective treatment of EGFR over-
expressing GBM reported so far, in an animal model. The
therapeutic strategy described here differs signiﬁcantly from
other EGFR targeted agents aimed at GBM, such as erlotinib,
geﬁtinib, [20] and anti-EGFR antibodies [21]. These agents
inhibit the activity of the receptor and its downstream
signaling. The response of GBM to geﬁtinib and erlotinib in
GBM is weak [22]. Furthermore, the response of non-small-
cell-lung cancer to either drug as a single agent is limited to
tumors in which the EGFR harbor mutations in the kinase
domain, where the EGFR is a survival element, and is usually
transient [23]. Mutations (extracellular) in the EGFR receptor
or frequent heterogeneity of GBM where only part of the cells
over-express EGFR will result in only partial response to
geﬁtinib and erlotinib as indeed observed in the recent
clinical trials [22]. In the case of anti-EGFR therapy, the
response seems not to be related to whether the EGFR is
mutated but these drugs are also not life saving in patients
with tumors involving EGFR [24]. The strategy described here
is different from those currently implemented therapies
because the EGFR is utilized to target a vehicle that delivers a
strong pro-apoptotic molecule, namely dsRNA. Due to the
strong bystander effect induced by the massive amount of
dsRNA on neighboring cancer cells that were not targeted
themselves, the therapy described here can eradicate EGFR
over-expressing tumors even when only half of the cells over-
express wt EGFR (Figure 5C). The bystander effect is
mediated at least partially by IFN-a (Figure 3B). This cytokine
is clinically used against various cancers including GBM.
Since IFN-a kills mainly fast proliferating cells, normal cells
should not be affected. Indeed, we did not detect any
pathology in normal brain tissue during or after the therapy
(Figure 6A).
Another important advantages of the therapy described
here are the fast cell killing (Figure 1) and activation of several
growth inhibitory pathways simultaneously (Figures 3A and
4). This form of therapy is likely to prevent and/or overcome
a potential mutation in one of the anti-proliferative proteins
and development of resistance to the therapy. This is
especially relevant for cancers with deﬁcient PKR activity
[25], because poly IC can still induce cell death in a PKR
independent manner (Figure 3A). We would like to suggest
that if this strategy is translated successfully to the clinical
setting it may indeed help patients with GBM. In fact, several
neurosurgery teams are interested in implementing this
therapy to clinic once all preclinical studies will be completed.
The elimination of EGFR over-expressing adenocarcinoma
and breast cancer in vivo (Figure 7C) suggests that in
principle this strategy can be applied to treat other cancers
that over-express EGFR. It should be emphasized that there
are a number of scenarios, other than GBM in which the local
application of the EGFR targeted poly IC is advantageous, like
head and neck cancer in which EGFR is over-expressed and
local therapies are often used.
Finally, we would like to suggest that the strategy of ligand-
guided delivery of dsRNA described here, can in principle, be
applied to other cancers in which a particular receptor is
over-expressed and undergoes endocytosis. Receptors that
are over-expressed in many tumors and qualify as candidates
Figure 6. In Vivo Selectivity of the Approach
(A) Pathological analysis of the brains. Intracranial tumors were
established and treated as described in Methods. After 24 h, animals
were sacrificed and ultrathin slices of the brains were prepared. Slices
were stained with H & E and analyzed by light microscopy (203
magnification) for development of pathological signs and immune cell
infiltration (yellow arrow). Bottom panel shows the example of slices
from the brains treated with (poly IC)PEI-PEG-EGFþPEI-Mel in the
experiment described in Figure 5A (7 d post-treatment).
(B) Poly IC induces apoptosis in intracranial xenografts. Intracranial
tumors were established and treated as described in Methods. Apoptotic
death was detected using Cell Death Detection kit-TMR Red (Methods).
White dashed lines represent borders of the tumors.
DOI: 10.1371/journal.pmed.0030006.g006
PLoS Medicine | www.plosmedicine.org January 2006 | Volume 3 | Issue 1 | e6 0133
Cancer-Specific Transfection of dsRNAfor targeting poly(IC) include the transferrin receptor [26],
the PDGF receptor [27] and the IGF-1 receptor [28].
Supporting Information
Figure S1. (poly IC)PEI-PEG-EGF(þPEI-Mel) Complexes Selectively
Kill U87MGwtEGFR Cells
Cells were seeded onto a 96-well plate at a density of 5,000 cells in 0.2
ml of medium per well and grown overnight. Cells were then
transfected as described [6,9] with poly IC at the indicated
concentrations using either PEI-PEG-EGF or PEI-PEG-EGFþPEI-Mel
(w/w ratio PEI-PEG-EGF:PEI-Mel¼1:10) complexes. The viability was
measured by the CellTiter-Glo Luminescent Cell Viability Assay
(Promega) according to the manufacturer’s instructions at 1 h after
transfection. Transfection with native PEI and Fugene6 (Roche) was
used to control for non-speciﬁc effect of poly IC. HBS stands for
transfection buffer alone [6].
Found at DOI: 10.1371/journal.pmed.0030006.sg001 (119 KB PDF).
Figure S2. Bystander Effect
For this assay, 500,000 U87MGwtEGFR cells were seeded onto 6-cm
Figure 7. Targeted Poly IC Eliminates Three Types of EGFR Over-Expressing Tumors
(A) (poly IC)Mel-PEI-PEG-EGF (MPPE) complexes prolong survival of mice bearing large intracranial U87MGwtEGFR xenografts. Cells were implanted into
the brains of 16 mice. 15 d later, two animals were sacrificed to measure the tumors (Methods). Other animals received the indicated treatments. The
daily doses of complexes were similar to the doses in Figure 3A and 3B. Survival of the animals was analyzed as above.
(B) Formulated poly IC selectively kills A431 and MDA-MB-468 cells. Cells were seeded in duplicate onto a 96-well plate at a density of 5,000 cells in 0.2
ml of medium per well and grown overnight. Cells were then transfected as described [6,9] with poly IC at the indicated concentrations using either
MPPE or PEI-PEG-EGFþPEI-Mel. Cell survival was measured by the Methylene blue assay at 48 h after transfection.
(C) (poly IC)MPPE complexes eliminate A431 and MDA-MB-468 xenografts in mice. A431 and MDA-MB-468 tumors were established and treated with
formulated poly IC as described in Methods. Tumors were measured daily. Control animals were euthanized at day 33 after treatment initiation. Poly IC
treated mice were kept alive to detect possible late recurrence of the tumors.
DOI: 10.1371/journal.pmed.0030006.g007
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Cancer-Specific Transfection of dsRNAplates, grown overnight in 2 ml of medium, and transfected with poly
IC at the indicated concentrations using PEI-PEG-EGFþPEI-Mel
complexes. Medium was collected at the indicated times after
transfection (x-axis). U87MG and U87MGDEGFR ‘‘indicator’’ cells
were seeded in 96-well plates (4,000 cells/well) and grown overnight in
200 ll of medium. 100 ll of medium was then replaced by the
medium collected from the transfected U87MGwtEGFR cells. In NR
samples, medium was not replaced. Growth inhibition was examined
48 h after medium exchange.
Found at DOI: 10.1371/journal.pmed.0030006.sg002 (35 KB PDF).
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Patient Summary
Background. Glioblastomas are the most frequent and the most
aggressive human brain tumors. Scientists have learned more about
these tumors in the past few years, but there are still very few treatment
options besides surgery and radiation, and only 3% of patients survive
longer than 5 years after diagnosis.
Why Was This Study Done? Over half of glioblastomas have a particular
characteristic: the cells that make up the tumor have 10–100 times more
of a particular molecule called EGFR on their surface than the
surrounding non-tumor cells. Taking advantage of that fact, the
researchers devised a strategy that used EGFR as a target to deliver a
treatment that they hoped would kill the tumor cells.
What Did the Researchers Do and Find? All of the experiments were
done with cultured cells, and some of them used mice in which tumors
had been implanted. The researchers created a mix of chemicals that
would latch on to the EGFR on the tumor cell surfaces, be taken up by
the tumor cells, and once inside the tumor cell would instruct it to
commit suicide. They found that this approach worked in cultured tumor
cells with lots of EGFR on their surfaces, and in mice that had brain
tumors comprised of such cells. They found that the treatment was quite
specific (that is, it killed the tumor cells and not the surrounding normal
brain tissue) and effective (all of the tumor cells seemed to have been
killed and the tumors didn’t grow back).
What Does This Mean? These results are encouraging. Many questions
need to be answered before we know whether this approach or a similar
one will be practical and efficient against human glioblastomas. Given
the lack of current options, it certainly seems worth pursuing, and the
researchers are currently preparing essential preclinical studies in which
a clinical-grade drug will be prepared, and its toxicity, distribution to
various organs, and other important analytical studies performed. At
present the authors examine in more detail the toxicity profile of the
poly IC complexed to the EGF receptor targeting vector.
Where Can I Find More Information Online? The following Web sites
provide information on brain cancer and glioblastomas.
National Brain Tumor Foundation in the US:
http://www.braintumor.org/
Cancer BACUP pages on brain cancer:
http://www.cancerbacup.org.uk/Cancertype/Brain
The Brain Tumor Society:
http://www.tbts.org/
NCI information pages on brain tumors:
http://www.cancer.gov/cancertopics/types/brain/
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